Treatment of pregnancy that occurs in cesarean scar with the aim of preserving the uterus: comparison between two minimally invasive methods
- Conditions
- CicatrixCesarean SectionG08.686.784.769
- Registration Number
- RBR-22hc4rm
- Lead Sponsor
- Escola Paulista de Medicina da Universidade Federal de São Paulo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
18 years of age or older; Hemodynamic stability, defined as diastolic blood pressure greater than or equal to 60 mmHg and systolic blood pressure greater than or equal to 90 mmHg, heart rate less than 100 bpm, and capillary refill time less than or equal to 3 seconds; Gestational age less than 12 weeks; Intact gestational sac in topography of the cesarean scar with embryo with heartbeat; Absence of signs of peritonism; Pregnancy in the exogenous cesarean section scar (COS-1); Myometrial mantle less than 5mm; Desire for a future pregnancy or not wanting to have a hysterectomy; Ease of returning to the hospital if necessary; Signed consent form
Hemoglobin less than 10 g/dl; Leukopenia (leukocytes less than 2,000 cells/mm3); Thrombocytopenia (platelets less than 100,000/mm3); Immunodeficiency, defined by the use of immunosuppressive drugs such as corticoids; Allergy to methotrexate; Current chronic lung disease, such as chronic obstructive pulmonary disease; Liver transaminases above the maximum reference value; Creatinine above the maximum reference value; Breastfeeding; Refusal to receive blood transfusion; Inability to continue the follow-up
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected to evaluate which of the minimally invasive methods is the most effective in preserving the patient's uterus after the treatment has been instituted, with success being considered if the patient progresses without the need for any additional intervention until ß-hCG levels are < 5mIU/ ml
- Secondary Outcome Measures
Name Time Method